Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice

Toxicology and Applied Pharmacology

Volumn 232, Issue 1, 2008, Pages 119-124

  Amirshahrokhi, K ^a   Dehpour, A R ^a   Hadjati, J ^a   Sotoudeh, M ^a   Ghazi Khansari, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Methadone; Multiple low dose streptozotocin; Type 1 diabetes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLUCOSE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; METHADONE; MU OPIATE RECEPTOR AGONIST; NALTREXONE; OPIATE ANTAGONIST; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LOW DRUG DOSE; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS ISLET BETA CELL; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; INSULIN; METHADONE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; PANCREAS; RECEPTORS, OPIOID, MU; STREPTOZOCIN; TIME FACTORS;

ANIMALIA; MUS;

EID: 51549102759     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.06.020     Document Type: Article

References (47)

1. Bach J.F. Therapeutic strategies in autoimmune diseases: the search for tolerance induction. Transplant Proc. 26 (1994) 3188-3190
2. Beales P.E. Problems with inducing tolerance to type 1 diabetes. Diabetes. Metab. Rev. 14 (1998) 257-258
3. Bencsics A., Elenkov I.J., and Vizi E.S. Effect of morphine on lipopolysaccharide-induced tumor necrosis factor-alpha production in vivo: involvement of the sympathetic nervous system. J. Neuroimmunol. 73 (1997) 1-6
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Bryant H.U., and Roudebush R.E. Suppressive effects of morphine pellet implants on in vivo parameters of immune function. J. Pharmacol. Exp. Ther. 255 (1990) 410-414
6. Budd K. Pain management: is opioid immunosuppression a clinical problem?. Biomed. Pharmacother. 60 (2006) 310-317
7. Cailleau C., Diu-Hercend A., Ruuth E., Westwood R., and Carnaud C. Treatment with neutralizing antibodies specific for IL-1beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46 (1997) 937-940
8. Cameron M.J., Arreaza G.A., Zucker P., Chensue S.W., Strieter R.M., Chakrabarti S., and Delovitch T.L. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159 (1997) 4686-4692
9. Gaveriaux-Ruff C., Matthes H.W., Peluso J., and Kieffer B.L. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6326-6330
10. Gysemans C.A., Ladriere L., Callewaert H., Rasschaert J., Flamez D., Levy D.E., Matthys P., Eizirik D.L., and Mathieu C. Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells. Diabetes 54 (2005) 2396-2403
11. Hancock W.W., Polanski M., Zhang J., Blogg N., and Weiner H.L. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am. J. Pathol. 147 (1995) 1193-1199
12. Herold K.C., Vezys V., Sun Q., Viktora D., Seung E., Reiner S., and Brown D.R. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J. Immunol. 156 (1996) 3521-3527
13. Holstad M., and Sandler S. A transcriptional inhibitor of TNF-alpha prevents diabetes induced by multiple low-dose streptozotocin injections in mice. J. Autoimmun. 16 (2001) 441-447
14. Karabatas L.M., Pastorale C., de Bruno L.F., Maschi F., Pivetta O.H., Lombardo Y.B., Chemes H., and Basabe J.C. Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice. Pancreas 30 (2005) 318-324
15. Kawasaki E., Abiru N., and Eguchi K. Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes. Res. Clin. Pract. 66 (2004) S27-S32
16. Kolb H. Immune intervention in type I diabetes mellitus-current clinical and experimental approaches. Exp. Clin. Endocrinol. 102 (1994) 269-272
17. Kristensen K., Christensen C.B., and Christrup L.L. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life. Sci. 56 (1995) 45-50
18. Lamhamedi-Cherradi S.E., Zheng S., Tisch R.M., and Chen Y.H. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52 (2003) 2274-2278
19. Levier D.G., Brown R.D., Musgrove D.L., Butterworth L.F., Mccay J.A., White K.L., Fuchs B.A., Harris L.S., and Munson A.E. The effect of methadone on the immune status of B6C3F1 mice. Fundam. Appl. Toxicol. 24 (1995) 275-284
20. Li Y., Wang X., Tian S., Guo C.J., Douglas S.D., and Ho W.Z. Methadone enhances human immunodeficiency virus infection of human immune cells. J. Infect. Dis. 185 (2002) 118-122
21. Like A.A., and Rossini A.A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193 (1976) 415-417
22. Mabley J.G., Pacher P., Southan G.J., Salzman A.L., and Szabo C. Nicotine reduces the incidence of type I diabetes in mice. J. Pharmacol. Exp. Ther. 300 (2002) 876-881
23. Mabley J.G., Rabinovitch A., Suarez-Pinzon W., Hasko G., Pacher P., Power R., Southan G., Salzman A., and Szabo C. Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol. Med. 9 (2003) 96-104
24. Maksimovic-Ivanic D., Trajkovic V., Miljkovic D.J., Mostarica S.M., and Stosic-Grujicic S. Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. Clin. Exp. Immunol. 129 (2002) 214-223
25. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., and Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 62 (2001) 111-123
26. Mehrishi J.N., and Mills I.H. Opiate receptors on lymphocytes and platelets in man. Clin. Immunol. Immunopathol. 27 (1983) 240-249
27. O'Brien B.A., Harmon B.V., Cameron D.P., and Allan D.J. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J. Pathol. 178 (1996) 176-181
28. Papaccio G., Pisanti F.A., Latronico M.V., Ammendola E., and Galdieri M. Multiple low-dose and single high-dose treatments with streptozotocin do not generate nitric oxide. J. Cell. Biochem. 77 (2000) 82-91
29. Pennline K.J., Roque-Gaffney E., and Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol. 71 (1994) 169-175
30. Pukel C., Baquerizo H., and Rabinovitch A. Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferon-gamma, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes 37 (1988) 133-136
31. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes. Metab. Rev. 14 (1998) 129-151
32. Rabinovitch A., and Suarez-Pinzon W.L. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol. 55 (1998) 1139-1149
33. Rees D.A., and Alcolado J.C. Animal models of diabetes mellitus. Diabet. Med. 22 (2005) 359-370
34. Rossini A.A., Williams R.M., Appel M.C., and Like A.A. Complete protection from low-dose streptozotocin-induced diabetes in mice. Nature 276 (1978) 182-184
35. Roy S., Barke R.A., and Loh H.H. MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Mol. Brain. Res. 61 (1998) 190-194
36. Roy S., Balasubramanian S., Sumandeep S., Charboneau R., Wang J., Melnyk D., Beilman G.J., Vatassery R., and Barke R.A. Morphine directs T cells toward T (H2) differentiation. Surgery 130 (2001) 304-309
37. Roy S., Wang J., Gupta S., Charboneau R., Loh H.H., and Barke R.A. Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet. J. Neuroimmunol. 147 (2004) 78-81
38. Roy S., Wang J., Charboneau R., Loh H.H., and Barke R.A. Morphine induces CD4+T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinase A pathway. J. Immunol. 175 (2005) 6361-6367
39. Rydgren T., Vaarala O., and Sandler S. Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J. Pharmacol. Exp. Ther. 323 (2007) 180-185
40. Sacerdote P., Di San Secondo V.E., Sirchia G., Manfredi B., and Panerai A.E. Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clin. Exp. Immunol. 113 (1998) 465-469
41. Sacerdote P., Manfredi B., Gaspani L., and Panerai A.E. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 95 (2000) 2031-2036
42. Suarez-Pinzon W.L., and Rabinovitch A. Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits. Int. J. Exp. Diabetes Res. 2 (2001) 3-17
43. Tabatabaie T., Waldon A.M., Jacob J.M., Floyd R.A., and Kotake Y. COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice. Biochem. Biophys. Res. Commun. 273 (2000) 699-704
44. Vallejo R., de Leon-Casasola O., and Benyamin R. Opioid therapy and immunosuppression: a review. Am. J. Ther. 11 (2004) 354-365
45. Wang J., Barke R.A., Charboneau R., Loh H.H., and Roy S. Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J. Biol. Chem. 278 (2003) 37622-37631
46. Yang Z., Chen M., Fialkow L.B., Ellett J.D., Wu R., and Nadler J.L. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas 26 (2003) 99-104
47. Zagon I.S., and McLaughlin P.J. Naltrexone modulates tumor response in mice with neuroblastoma. Science 12 (1983) 671-673